These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23978325)

  • 1. High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia.
    Vijayaraghavan S; Maetzler W; Reimold M; Lithner CU; Liepelt-Scarfone I; Berg D; Darreh-Shori T
    Alzheimers Dement; 2014 Sep; 10(5):530-540.e1. PubMed ID: 23978325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study.
    Degerman Gunnarsson M; Lindau M; Wall A; Blennow K; Darreh-Shori T; Basu S; Nordberg A; Larsson A; Lannfelt L; Basun H; Kilander L
    Dement Geriatr Cogn Disord; 2010; 29(3):204-12. PubMed ID: 20332638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
    Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
    Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging beta-amyloid burden in aging and dementia.
    Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
    Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
    de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
    Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias.
    Geng C; Tan L; Chen C
    Brain Res; 2024 Jun; 1833():148881. PubMed ID: 38519009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ApoE and clusterin CSF levels influence associations between APOE genotype and changes in CSF tau, but not CSF Aβ42, levels in non-demented elderly.
    Slot RER; Kester MI; Van Harten AC; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM; Veerhuis R
    Neurobiol Aging; 2019 Jul; 79():101-109. PubMed ID: 31029938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
    Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
    J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
    Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
    Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients.
    Huey ED; Mirza N; Putnam KT; Soares H; Csako G; Levy JA; Copenhaver B; Cohen RM; Sunderland T
    Dement Geriatr Cogn Disord; 2006; 22(1):48-53. PubMed ID: 16682793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.